, Volume 14, Issue 3, pp 698–715 | Cite as

HCN Channel Targets for Novel Antidepressant Treatment



Major depressive disorder (MDD) is a chronic and potentially life threatening illness that carries a staggering global burden. Characterized by depressed mood, MDD is often difficult to diagnose and treat owing to heterogeneity of syndrome and complex etiology. Contemporary antidepressant treatments are based on improved monoamine-based formulations from serendipitous discoveries made > 60 years ago. Novel antidepressant treatments are necessary, as roughly half of patients using available antidepressants do not see long-term remission of depressive symptoms. Current development of treatment options focuses on generating efficacious antidepressants, identifying depression-related neural substrates, and better understanding the pathophysiological mechanisms of depression. Recent insight into the brain’s mesocorticolimbic circuitry from animal models of depression underscores the importance of ionic mechanisms in neuronal homeostasis and dysregulation, and substantial evidence highlights a potential role for ion channels in mediating depression-related excitability changes. In particular, hyperpolarization-activated cyclic nucleotide-gated (HCN) channels are essential regulators of neuronal excitability. In this review, we describe seminal research on HCN channels in the prefrontal cortex and hippocampus in stress and depression-related behaviors, and highlight substantial evidence within the ventral tegmental area supporting the development of novel therapeutics targeting HCN channels in MDD. We argue that methods targeting the activity of reward-related brain areas have significant potential as superior treatments for depression.


Depression antidepressants HCN channels Ih current neuronal excitability 



This work was supported by grants from the National Institute of Mental Health (M.H.H., R21MH112081; S.M.K., F31MH108326), and the Brain and Behavior Research Foundation (M.H.H., NARSAD). We thank Dr. Madeline L. Pfau for critical reading of the review.

Required Author Forms

Disclosure forms provided by the authors are available with the online version of this article.

Supplementary material

13311_2017_538_MOESM1_ESM.pdf (1.2 mb)
ESM 1 (PDF 1224 kb)


  1. 1.
    Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):617-27.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53(8):649-59.PubMedCrossRefGoogle Scholar
  3. 3.
    Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157(2):229-33.PubMedCrossRefGoogle Scholar
  4. 4.
    American Psychiatric Association., American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders : DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013. xliv, 947 p. p.Google Scholar
  5. 5.
    Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-17.PubMedCrossRefGoogle Scholar
  6. 6.
    Gartlehner G, Thaler K, Hill S, Hansen RA. How should primary care doctors select which antidepressants to administer? Current psychiatry reports. 2012;14(4):360-9.PubMedCrossRefGoogle Scholar
  7. 7.
    Stahl SM. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry. 1998;59 Suppl 4:5-14.PubMedGoogle Scholar
  8. 8.
    Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. Journal of occupational and environmental medicine. 2008;50(4):428-36.PubMedCrossRefGoogle Scholar
  9. 9.
    Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-105.PubMedCrossRefGoogle Scholar
  10. 10.
    Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965;122(5):509-22.PubMedCrossRefGoogle Scholar
  11. 11.
    Duman RS, Aghajanian GK, Sanacora G, Krystal JH. Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med. 2016;22(3):238-49.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-27.PubMedCrossRefGoogle Scholar
  13. 13.
    Vialou V, Feng J, Robison AJ, Nestler EJ. Epigenetic mechanisms of depression and antidepressant action. Annu Rev Pharmacol Toxicol. 2013;53:59-87.PubMedCrossRefGoogle Scholar
  14. 14.
    Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus. 2006;16(3):239-49.PubMedCrossRefGoogle Scholar
  15. 15.
    Christoffel DJ, Golden SA, Russo SJ. Structural and synaptic plasticity in stress-related disorders. Rev Neurosci. 2011;22(5):535-49.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Castren E, Hen R. Neuronal plasticity and antidepressant actions. Trends in neurosciences. 2013;36(5):259-67.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Willner P, Scheel-Kruger J, Belzung C. The neurobiology of depression and antidepressant action. Neurosci Biobehav Rev. 2013;37(10 Pt 1):2331-71.PubMedCrossRefGoogle Scholar
  18. 18.
    Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894-902.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Kavalali ET, Monteggia LM. Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry. 2012;169(11):1150-6.PubMedCrossRefGoogle Scholar
  20. 20.
    Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry. 2006;63(10):1121-9.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Drevets WC, Zarate CA, Jr., Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review. Biol Psychiatry. 2013;73(12):1156-63.PubMedCrossRefGoogle Scholar
  22. 22.
    Voleti B, Navarria A, Liu RJ, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74(10):742-9.PubMedCrossRefGoogle Scholar
  23. 23.
    Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475(7354):91-5.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4.PubMedCrossRefGoogle Scholar
  25. 25.
    Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.PubMedCrossRefGoogle Scholar
  26. 26.
    Wohleb ES, Gerhard D, Thomas A, Duman RS. Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine. Curr Neuropharmacol. 2017;15(1):11-20.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Gerhard DM, Wohleb ES, Duman RS. Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today. 2016;21(3):454-64.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Kessler RC. The effects of stressful life events on depression. Annual review of psychology. 1997;48:191-214.PubMedCrossRefGoogle Scholar
  29. 29.
    Lucki I. The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol. 1997;8(6-7):523-32.PubMedCrossRefGoogle Scholar
  30. 30.
    Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266(5604):730-2.PubMedCrossRefGoogle Scholar
  31. 31.
    Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85(3):367-70.PubMedCrossRefGoogle Scholar
  32. 32.
    Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005;29(4-5):571-625.PubMedCrossRefGoogle Scholar
  33. 33.
    Henn FA, Vollmayr B. Stress models of depression: forming genetically vulnerable strains. Neurosci Biobehav Rev. 2005;29(4-5):799-804.PubMedCrossRefGoogle Scholar
  34. 34.
    Li B, Piriz J, Mirrione M, et al. Synaptic potentiation onto habenula neurons in the learned helplessness model of depression. Nature. 2011;470(7335):535-9.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Nestler EJ, Hyman SE. Animal models of neuropsychiatric disorders. Nature Neuroscience. 2010;13(10):1161-9.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Willner P. Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology (Berl). 1997;134(4):319-29.PubMedCrossRefGoogle Scholar
  37. 37.
    Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology. 2005;52(2):90-110.PubMedCrossRefGoogle Scholar
  38. 38.
    Hodes GE, Pfau ML, Purushothaman I, et al. Sex Differences in Nucleus Accumbens Transcriptome Profiles Associated with Susceptibility versus Resilience to Subchronic Variable Stress. J Neurosci. 2015;35(50):16362-76.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science. 2006;311(5762):864-8.PubMedCrossRefGoogle Scholar
  40. 40.
    Krishnan V, Han MH, Graham DL, Berton O, Renthal W, Russo SJ, et al. Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell. 2007;131(2):391-404.PubMedCrossRefGoogle Scholar
  41. 41.
    Cao JL, Covington HE, 3rd, Friedman AK, et al. Mesolimbic dopamine neurons in the brain reward circuit mediate susceptibility to social defeat and antidepressant action. J Neurosci. 2010;30(49):16453-8.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Chaudhury D, Walsh JJ, Friedman AK, et al. Rapid regulation of depression-related behaviours by control of midbrain dopamine neurons. Nature. 2013;493(7433):532-6.PubMedCrossRefGoogle Scholar
  43. 43.
    Friedman AK, Walsh JJ, Juarez B, et al. Enhancing depression mechanisms in midbrain dopamine neurons achieves homeostatic resilience. Science. 2014;344(6181):313-9.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Feder A, Nestler EJ, Charney DS. Psychobiology and molecular genetics of resilience. Nat Rev Neurosci. 2009;10(6):446-57.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Russo SJ, Murrough JW, Han MH, Charney DS, Nestler EJ. Neurobiology of resilience. Nat Neurosci. 2012;15(11):1475-84.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Friedman AK, Juarez B, Ku SM, et al. KCNQ channel openers reverse depressive symptoms via an active resilience mechanism. Nat Commun. 2016;7:11671.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Walsh JJ, Friedman AK, Sun H, et al. Stress and CRF gate neural activation of BDNF in the mesolimbic reward pathway. Nat Neurosci. 2014;17(1):27-9.PubMedCrossRefGoogle Scholar
  48. 48.
    Friedman A. Neuroscience. Jump-starting natural resilience reverses stress susceptibility. Science. 2014;346(6209):555.Google Scholar
  49. 49.
    Golden SA, Covington HE, Berton O, Russo SJ. A standardized protocol for repeated social defeat stress in mice. Nature Protocols. 2011;6(8):1183-91.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Pfau ML, Russo SJ. Peripheral and Central Mechanisms of Stress Resilience. Neurobiol Stress. 2015;1:66-79.PubMedCrossRefGoogle Scholar
  51. 51.
    Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci. 1997;9(3):471-81.PubMedCrossRefGoogle Scholar
  52. 52.
    Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000;48(8):830-43.PubMedCrossRefGoogle Scholar
  53. 53.
    Mayberg HS, Lozano AM, Voon V, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651-60.PubMedCrossRefGoogle Scholar
  54. 54.
    Schlaepfer TE, Cohen MX, Frick C, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008;33(2):368-77.PubMedCrossRefGoogle Scholar
  55. 55.
    Krishnan V, Han MH, Mazei-Robison M, et al. AKT signaling within the ventral tegmental area regulates cellular and behavioral responses to stressful stimuli. Biol Psychiatry. 2008;64(8):691-700.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Covington HE, 3rd, Lobo MK, Maze I, et al. Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex. J Neurosci. 2010;30(48):16082-90.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Vialou V, Robison AJ, Laplant QC, et al. DeltaFosB in brain reward circuits mediates resilience to stress and antidepressant responses. Nat Neurosci. 2010;13(6):745-52.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Christoffel DJ, Golden SA, Dumitriu D, et al. IkappaB kinase regulates social defeat stress-induced synaptic and behavioral plasticity. J Neurosci. 2011;31(1):314-21.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Bagot RC, Parise EM, Pena CJ, et al. Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression. Nat Commun. 2015;6:7062.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Nestler EJ, Carlezon WA, Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry. 2006;59(12):1151-9.PubMedCrossRefGoogle Scholar
  61. 61.
    Delvecchio G, Fossati P, Boyer P, et al. Common and distinct neural correlates of emotional processing in Bipolar Disorder and Major Depressive Disorder: a voxel-based meta-analysis of functional magnetic resonance imaging studies. Eur Neuropsychopharmacol. 2012;22(2):100-13.PubMedCrossRefGoogle Scholar
  62. 62.
    Anand A, Li Y, Wang Y, Gardner K, Lowe MJ. Reciprocal effects of antidepressant treatment on activity and connectivity of the mood regulating circuit: an FMRI study. J Neuropsychiatry Clin Neurosci. 2007;19(3):274-82.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp. 2008;29(6):683-95.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Monteggia LM, Eisch AJ, Tang MD, Kaczmarek LK, Nestler EJ. Cloning and localization of the hyperpolarization-activated cyclic nucleotide-gated channel family in rat brain. Brain research Molecular brain research. 2000;81(1-2):129-39.PubMedCrossRefGoogle Scholar
  65. 65.
    Ludwig A, Zong X, Jeglitsch M, Hofmann F, Biel M. A family of hyperpolarization-activated mammalian cation channels. Nature. 1998;393(6685):587-91.PubMedCrossRefGoogle Scholar
  66. 66.
    Robinson RB, Siegelbaum SA. Hyperpolarization-activated cation currents: from molecules to physiological function. Annu Rev Physiol. 2003;65:453-80.PubMedCrossRefGoogle Scholar
  67. 67.
    Nolan MF, Malleret G, Dudman JT, et al. A behavioral role for dendritic integration: HCN1 channels constrain spatial memory and plasticity at inputs to distal dendrites of CA1 pyramidal neurons. Cell. 2004;119(5):719-32.PubMedGoogle Scholar
  68. 68.
    Wahl-Schott C, Biel M. HCN channels: structure, cellular regulation and physiological function. Cell Mol Life Sci. 2009;66(3):470-94.PubMedCrossRefGoogle Scholar
  69. 69.
    Notomi T, Shigemoto R. Immunohistochemical localization of Ih channel subunits, HCN1-4, in the rat brain. J Comp Neurol. 2004;471(3):241-76.PubMedCrossRefGoogle Scholar
  70. 70.
    Moosmang S, Stieber J, Zong X, Biel M, Hofmann F, Ludwig A. Cellular expression and functional characterization of four hyperpolarization-activated pacemaker channels in cardiac and neuronal tissues. European journal of biochemistry. 2001;268(6):1646-52.PubMedCrossRefGoogle Scholar
  71. 71.
    Brewster AL, Chen Y, Bender RA, Yeh A, Shigemoto R, Baram TZ. Quantitative analysis and subcellular distribution of mRNA and protein expression of the hyperpolarization-activated cyclic nucleotide-gated channels throughout development in rat hippocampus. Cereb Cortex. 2007;17(3):702-12.PubMedCrossRefGoogle Scholar
  72. 72.
    Surges R, Freiman TM, Feuerstein TJ. Input resistance is voltage dependent due to activation of Ih channels in rat CA1 pyramidal cells. J Neurosci Res. 2004;76(4):475-80.PubMedCrossRefGoogle Scholar
  73. 73.
    Lamas JA. A hyperpolarization-activated cation current (Ih) contributes to resting membrane potential in rat superior cervical sympathetic neurones. Pflugers Arch. 1998;436(3):429-35.PubMedCrossRefGoogle Scholar
  74. 74.
    Nolan MF, Dudman JT, Dodson PD, Santoro B. HCN1 channels control resting and active integrative properties of stellate cells from layer II of the entorhinal cortex. J Neurosci. 2007;27(46):12440-51.PubMedCrossRefGoogle Scholar
  75. 75.
    Okamoto T, Harnett MT, Morikawa H. Hyperpolarization-activated cation current (Ih) is an ethanol target in midbrain dopamine neurons of mice. J Neurophysiol. 2006;95(2):619-26.PubMedCrossRefGoogle Scholar
  76. 76.
    Neuhoff H, Neu A, Liss B, Roeper J. I(h) channels contribute to the different functional properties of identified dopaminergic subpopulations in the midbrain. J Neurosci. 2002;22(4):1290-302.PubMedGoogle Scholar
  77. 77.
    Magee JC. Dendritic lh normalizes temporal summation in hippocampal CA1 neurons. Nat Neurosci. 1999;2(6):508-14.PubMedCrossRefGoogle Scholar
  78. 78.
    Lorincz A, Notomi T, Tamas G, Shigemoto R, Nusser Z. Polarized and compartment-dependent distribution of HCN1 in pyramidal cell dendrites. Nat Neurosci. 2002;5(11):1185-93.PubMedCrossRefGoogle Scholar
  79. 79.
    Beaumont V, Zucker RS. Enhancement of synaptic transmission by cyclic AMP modulation of presynaptic Ih channels. Nat Neurosci. 2000;3(2):133-41.PubMedCrossRefGoogle Scholar
  80. 80.
    He C, Chen F, Li B, Hu Z. Neurophysiology of HCN channels: from cellular functions to multiple regulations. Prog Neurobiol. 2014;112:1-23.PubMedCrossRefGoogle Scholar
  81. 81.
    Bender RA, Kirschstein T, Kretz O, et al. Localization of HCN1 channels to presynaptic compartments: novel plasticity that may contribute to hippocampal maturation. J Neurosci. 2007;27(17):4697-706.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Poolos NP, Migliore M, Johnston D. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Nat Neurosci. 2002;5(8):767-74.PubMedGoogle Scholar
  83. 83.
    Huang Z, Lujan R, Martinez-Hernandez J, Lewis AS, Chetkovich DM, Shah MM. TRIP8b-independent trafficking and plasticity of adult cortical presynaptic HCN1 channels. J Neurosci. 2012;32(42):14835-48.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Thuault SJ, Malleret G, Constantinople CM, et al. Prefrontal cortex HCN1 channels enable intrinsic persistent neural firing and executive memory function. J Neurosci. 2013;33(34):13583-99.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Brager DH, Lewis AS, Chetkovich DM, Johnston D. Short- and long-term plasticity in CA1 neurons from mice lacking h-channel auxiliary subunit TRIP8b. J Neurophysiol. 2013;110(10):2350-7.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    He W, Xu X, Lv Q, Guo L. Low dose ZD7288 attenuates the ischemia/reperfusion-induced impairment of long-term potentiation induction at hippocampal Schaffer collateral-CA1 synapses. Cell Mol Neurobiol. 2014;34(4):611-7.PubMedCrossRefGoogle Scholar
  87. 87.
    Kelmendi B, Holsbach-Beltrame M, McIntosh AM, et al. Association of polymorphisms in HCN4 with mood disorders and obsessive compulsive disorder. Neurosci Lett. 2011;496(3):195-9.PubMedPubMedCentralCrossRefGoogle Scholar
  88. 88.
    McIntosh AM, Simen AA, Evans KL, et al. Genetic variation in Hyperpolarization-activated cyclic nucleotide-gated channels and its relationship with neuroticism, cognition and risk of depression. Front Genet. 2012;3:116.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Dunlop J, Vasilyev D, Lu P, Cummons T, Bowlby MR. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and pain. Curr Pharm Des. 2009;15(15):1767-72.PubMedCrossRefGoogle Scholar
  90. 90.
    Baruscotti M, Bucchi A, Difrancesco D. Physiology and pharmacology of the cardiac pacemaker ("funny") current. Pharmacol Ther. 2005;107(1):59-79.PubMedCrossRefGoogle Scholar
  91. 91.
    Noam Y, Zha Q, Phan L, et al. Trafficking and surface expression of hyperpolarization-activated cyclic nucleotide-gated channels in hippocampal neurons. J Biol Chem. 2010;285(19):14724-36.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Santoro B, Piskorowski RA, Pian P, Hu L, Liu H, Siegelbaum SA. TRIP8b splice variants form a family of auxiliary subunits that regulate gating and trafficking of HCN channels in the brain. Neuron. 2009;62(6):802-13.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Lewis AS, Schwartz E, Chan CS, Noam Y, Shin M, Wadman WJ, et al. Alternatively spliced isoforms of TRIP8b differentially control h channel trafficking and function. J Neurosci. 2009;29(19):6250-65.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Lewis AS, Vaidya SP, Blaiss CA, et al. Deletion of the hyperpolarization-activated cyclic nucleotide-gated channel auxiliary subunit TRIP8b impairs hippocampal Ih localization and function and promotes antidepressant behavior in mice. J Neurosci. 2011;31(20):7424-40.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Kim JJ, Yoon KS. Stress: metaplastic effects in the hippocampus. Trends in neurosciences. 1998;21(12):505-9.PubMedCrossRefGoogle Scholar
  96. 96.
    Sapolsky RM. Depression, antidepressants, and the shrinking hippocampus. Proc Natl Acad Sci U S A. 2001;98(22):12320-2.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Kennedy SH, Evans KR, Kruger S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry. 2001;158(6):899-905.PubMedCrossRefGoogle Scholar
  98. 98.
    Campbell S, MacQueen G. An update on regional brain volume differences associated with mood disorders. Curr Opin Psychiatry. 2006;19(1):25-33.PubMedCrossRefGoogle Scholar
  99. 99.
    Campbell S, Macqueen G. The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci. 2004;29(6):417-26.PubMedPubMedCentralGoogle Scholar
  100. 100.
    Campbell S, Marriott M, Nahmias C, MacQueen GM. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry. 2004;161(4):598-607.PubMedCrossRefGoogle Scholar
  101. 101.
    Fan Y, Fricker D, Brager DH, et al. Activity-dependent decrease of excitability in rat hippocampal neurons through increases in I(h). Nat Neurosci. 2005;8(11):1542-51.PubMedCrossRefGoogle Scholar
  102. 102.
    Magee JC. Dendritic hyperpolarization-activated currents modify the integrative properties of hippocampal CA1 pyramidal neurons. J Neurosci. 1998;18(19):7613-24.PubMedGoogle Scholar
  103. 103.
    Tsay D, Dudman JT, Siegelbaum SA. HCN1 channels constrain synaptically evoked Ca2+ spikes in distal dendrites of CA1 pyramidal neurons. Neuron. 2007;56(6):1076-89.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Magee JC. Dendritic integration of excitatory synaptic input. Nat Rev Neurosci. 2000;1(3):181-90.PubMedCrossRefGoogle Scholar
  105. 105.
    Hu H, Vervaeke K, Storm JF. Two forms of electrical resonance at theta frequencies, generated by M-current, h-current and persistent Na+ current in rat hippocampal pyramidal cells. J Physiol. 2002;545(Pt 3):783-805.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Narayanan R, Johnston D. The h channel mediates location dependence and plasticity of intrinsic phase response in rat hippocampal neurons. J Neurosci. 2008;28(22):5846-60.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Narayanan R, Johnston D. Long-term potentiation in rat hippocampal neurons is accompanied by spatially widespread changes in intrinsic oscillatory dynamics and excitability. Neuron. 2007;56(6):1061-75.PubMedPubMedCentralCrossRefGoogle Scholar
  108. 108.
    Kim CS, Chang PY, Johnston D. Enhancement of dorsal hippocampal activity by knockdown of HCN1 channels leads to anxiolytic- and antidepressant-like behaviors. Neuron. 2012;75(3):503-16.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Han Y, Heuermann RJ, Lyman KA, Fisher D, Ismail QA, Chetkovich DM. HCN-channel dendritic targeting requires bipartite interaction with TRIP8b and regulates antidepressant-like behavioral effects. Mol Psychiatry. 2016.Google Scholar
  110. 110.
    Day M, Carr DB, Ulrich S, Ilijic E, Tkatch T, Surmeier DJ. Dendritic excitability of mouse frontal cortex pyramidal neurons is shaped by the interaction among HCN, Kir2, and Kleak channels. J Neurosci. 2005;25(38):8776-87.PubMedCrossRefGoogle Scholar
  111. 111.
    Arnsten AF. Stress weakens prefrontal networks: molecular insults to higher cognition. Nat Neurosci. 2015;18(10):1376-85.PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Arnsten AF. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009;10(6):410-22.PubMedPubMedCentralCrossRefGoogle Scholar
  113. 113.
    Wang M, Ramos BP, Paspalas CD, et al. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129(2):397-410.PubMedCrossRefGoogle Scholar
  114. 114.
    Paspalas CD, Wang M, Arnsten AF. Constellation of HCN channels and cAMP regulating proteins in dendritic spines of the primate prefrontal cortex: potential substrate for working memory deficits in schizophrenia. Cereb Cortex. 2013;23(7):1643-54.PubMedCrossRefGoogle Scholar
  115. 115.
    Gamo NJ, Lur G, Higley MJ, et al. Stress Impairs Prefrontal Cortical Function via D1 Dopamine Receptor Interactions With Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels. Biol Psychiatry. 2015;78(12):860-70.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007;17 Suppl 1:i6-15.PubMedCrossRefGoogle Scholar
  117. 117.
    Birnbaum S, Gobeske KT, Auerbach J, Taylor JR, Arnsten AF. A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol Psychiatry. 1999;46(9):1266-74.PubMedCrossRefGoogle Scholar
  118. 118.
    Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci. 2007;10(3):376-84.PubMedCrossRefGoogle Scholar
  119. 119.
    Chen S, Wang J, Siegelbaum SA. Properties of hyperpolarization-activated pacemaker current defined by coassembly of HCN1 and HCN2 subunits and basal modulation by cyclic nucleotide. J Gen Physiol. 2001;117(5):491-504.PubMedPubMedCentralCrossRefGoogle Scholar
  120. 120.
    Ulens C, Tytgat J. Functional heteromerization of HCN1 and HCN2 pacemaker channels. J Biol Chem. 2001;276(9):6069-72.PubMedCrossRefGoogle Scholar
  121. 121.
    Aoki C, Venkatesan C, Kurose H. Noradrenergic modulation of the prefrontal cortex as revealed by electron microscopic immunocytochemistry. Adv Pharmacol. 1998;42:777-80.PubMedCrossRefGoogle Scholar
  122. 122.
    Aoki C, Venkatesan C, Go CG, Forman R, Kurose H. Cellular and subcellular sites for noradrenergic action in the monkey dorsolateral prefrontal cortex as revealed by the immunocytochemical localization of noradrenergic receptors and axons. Cereb Cortex. 1998;8(3):269-77.PubMedCrossRefGoogle Scholar
  123. 123.
    Goldman-Rakic PS, Lidow MS, Gallager DW. Overlap of dopaminergic, adrenergic, and serotoninergic receptors and complementarity of their subtypes in primate prefrontal cortex. J Neurosci. 1990;10(7):2125-38.PubMedGoogle Scholar
  124. 124.
    Vargas G, Lucero MT. Modulation by PKA of the hyperpolarization-activated current (Ih) in cultured rat olfactory receptor neurons. J Membr Biol. 2002;188(2):115-25.PubMedCrossRefGoogle Scholar
  125. 125.
    Packard MG, Teather LA. Amygdala modulation of multiple memory systems: hippocampus and caudate-putamen. Neurobiol Learn Mem. 1998;69(2):163-203.PubMedCrossRefGoogle Scholar
  126. 126.
    Thierry AM, Tassin JP, Blanc G, Glowinski J. Selective activation of mesocortical DA system by stress. Nature. 1976;263(5574):242-4.PubMedCrossRefGoogle Scholar
  127. 127.
    Inglis FM, Moghaddam B. Dopaminergic innervation of the amygdala is highly responsive to stress. J Neurochem. 1999;72(3):1088-94.PubMedCrossRefGoogle Scholar
  128. 128.
    Abercrombie ED, Keefe KA, DiFrischia DS, Zigmond MJ. Differential effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem. 1989;52(5):1655-8.PubMedCrossRefGoogle Scholar
  129. 129.
    Tidey JW, Miczek KA. Social defeat stress selectively alters mesocorticolimbic dopamine release: an in vivo microdialysis study. Brain Res. 1996;721(1-2):140-9.PubMedCrossRefGoogle Scholar
  130. 130.
    Arencibia-Albite F, Paladini C, Williams JT, Jimenez-Rivera CA. Noradrenergic modulation of the hyperpolarization-activated cation current (Ih) in dopamine neurons of the ventral tegmental area. Neuroscience. 2007;149(2):303-14.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Lammel S, Hetzel A, Hackel O, Jones I, Liss B, Roeper J. Unique properties of mesoprefrontal neurons within a dual mesocorticolimbic dopamine system. Neuron. 2008;57(5):760-73.PubMedCrossRefGoogle Scholar
  132. 132.
    Wanat MJ, Hopf FW, Stuber GD, Phillips PE, Bonci A. Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. J Physiol. 2008;586(8):2157-70.PubMedPubMedCentralCrossRefGoogle Scholar
  133. 133.
    Franz O, Liss B, Neu A, Roeper J. Single-cell mRNA expression of HCN1 correlates with a fast gating phenotype of hyperpolarization-activated cyclic nucleotide-gated ion channels (Ih) in central neurons. Eur J Neurosci. 2000;12(8):2685-93.PubMedCrossRefGoogle Scholar
  134. 134.
    Schultz W, Dayan P, Montague PR. A neural substrate of prediction and reward. Science. 1997;275(5306):1593-9.PubMedCrossRefGoogle Scholar
  135. 135.
    Matsumoto M, Hikosaka O. Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature. 2009;459(7248):837-41.PubMedPubMedCentralCrossRefGoogle Scholar
  136. 136.
    Brischoux F, Chakraborty S, Brierley DI, Ungless MA. Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. Proc Natl Acad Sci U S A. 2009;106(12):4894-9.PubMedPubMedCentralCrossRefGoogle Scholar
  137. 137.
    Grace AA, Floresco SB, Goto Y, Lodge DJ. Regulation of firing of dopaminergic neurons and control of goal-directed behaviors. Trends in neurosciences. 2007;30(5):220-7.PubMedCrossRefGoogle Scholar
  138. 138.
    Schultz W. Behavioral dopamine signals. Trends in neurosciences. 2007;30(5):203-10.PubMedCrossRefGoogle Scholar
  139. 139.
    Tye KM, Mirzabekov JJ, Warden MR, et al. Dopamine neurons modulate neural encoding and expression of depression-related behaviour. Nature. 2013;493(7433):537-41.PubMedCrossRefGoogle Scholar
  140. 140.
    Ungless MA, Grace AA. Are you or aren't you? Challenges associated with physiologically identifying dopamine neurons. Trends in neurosciences. 2012;35(7):422-30.PubMedPubMedCentralCrossRefGoogle Scholar
  141. 141.
    Lacey MG, Mercuri NB, North RA. Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids. J Neurosci. 1989;9(4):1233-41.PubMedGoogle Scholar
  142. 142.
    Margolis EB, Lock H, Hjelmstad GO, Fields HL. The ventral tegmental area revisited: is there an electrophysiological marker for dopaminergic neurons? J Physiol. 2006;577(Pt 3):907-24.PubMedPubMedCentralCrossRefGoogle Scholar
  143. 143.
    Walsh JJ, Han MH. The heterogeneity of ventral tegmental area neurons: Projection functions in a mood-related context. Neuroscience. 2014;282:101-8.PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Juarez B, Han MH. Diversity of Dopaminergic Neural Circuits in Response to Drug Exposure. Neuropsychopharmacology. 2016;41(10):2424-46.PubMedPubMedCentralCrossRefGoogle Scholar
  145. 145.
    Frye MA. Clinical practice. Bipolar disorder--a focus on depression. N Engl J Med. 2011;364(1):51-9.PubMedCrossRefGoogle Scholar
  146. 146.
    Poolos NP, Warner LN, Humphreys SZ, Williams S. Comparative efficacy of combination drug therapy in refractory epilepsy. Neurology. 2012;78(1):62-8.PubMedCrossRefGoogle Scholar
  147. 147.
    Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat Neurosci. 2005;8(9):1263-8.PubMedCrossRefGoogle Scholar
  148. 148.
    Zhang F, Wang LP, Boyden ES, Deisseroth K. Channelrhodopsin-2 and optical control of excitable cells. Nat Methods. 2006;3(10):785-92.PubMedCrossRefGoogle Scholar
  149. 149.
    Inyushin MU, Arencibia-Albite F, Vazquez-Torres R, Velez-Hernandez ME, Jimenez-Rivera CA. Alpha-2 noradrenergic receptor activation inhibits the hyperpolarization-activated cation current (Ih) in neurons of the ventral tegmental area. Neuroscience. 2010;167(2):287-97.PubMedPubMedCentralCrossRefGoogle Scholar
  150. 150.
    Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev. 2001;53(2):209-43.PubMedGoogle Scholar
  151. 151.
    Hauger RL, Risbrough V, Brauns O, Dautzenberg FM. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets. 2006;5(4):453-79.PubMedPubMedCentralCrossRefGoogle Scholar
  152. 152.
    Nestler EJ, Hope BT, Widnell KL. Drug addiction: a model for the molecular basis of neural plasticity. Neuron. 1993;11(6):995-1006.PubMedCrossRefGoogle Scholar
  153. 153.
    Turrigiano G. Too many cooks? Intrinsic and synaptic homeostatic mechanisms in cortical circuit refinement. Annu Rev Neurosci. 2011;34:89-103.PubMedCrossRefGoogle Scholar
  154. 154.
    Han MH, Nestler EJ. Neural Substrates of Depression and Resilience. Neurotherapeutics. 2017.Google Scholar
  155. 155.
    Delmas P, Brown DA. Pathways modulating neural KCNQ/M (Kv7) potassium channels. Nat Rev Neurosci. 2005;6(11):850-62.PubMedCrossRefGoogle Scholar
  156. 156.
    George MS, Abbott LF, Siegelbaum SA. HCN hyperpolarization-activated cation channels inhibit EPSPs by interactions with M-type K(+) channels. Nat Neurosci. 2009;12(5):577-84.PubMedPubMedCentralCrossRefGoogle Scholar
  157. 157.
    Wang HS, Pan Z, Shi W, et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science. 1998;282(5395):1890-3.PubMedCrossRefGoogle Scholar
  158. 158.
    Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat Rev Drug Discov. 2009;8(12):982-1001.PubMedPubMedCentralCrossRefGoogle Scholar
  159. 159.
    Hernandez CC, Zaika O, Tolstykh GP, Shapiro MS. Regulation of neural KCNQ channels: signalling pathways, structural motifs and functional implications. J Physiol. 2008;586(7):1811-21.PubMedPubMedCentralCrossRefGoogle Scholar
  160. 160.
    Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci. 2001;21(15):5535-45.PubMedGoogle Scholar
  161. 161.
    Korsgaard MP, Hartz BP, Brown WD, Ahring PK, Strobaek D, Mirza NR. Anxiolytic effects of Maxipost (BMS-204352) and retigabine via activation of neuronal Kv7 channels. J Pharmacol Exp Ther. 2005;314(1):282-92.PubMedCrossRefGoogle Scholar
  162. 162.
    Sotty F, Damgaard T, Montezinho LP, et al. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J Pharmacol Exp Ther. 2009;328(3):951-62.PubMedCrossRefGoogle Scholar
  163. 163.
    Dencker D, Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res. 2010;207(1):78-83.PubMedCrossRefGoogle Scholar
  164. 164.
    Wang M, Gamo NJ, Yang Y, et al. Neuronal basis of age-related working memory decline. Nature. 2011;476(7359):210-3.PubMedPubMedCentralCrossRefGoogle Scholar
  165. 165.
    Stafstrom CE, Grippon S, Kirkpatrick P. Ezogabine (retigabine). Nat Rev Drug Discov. 2011;10(10):729-30.PubMedCrossRefGoogle Scholar
  166. 166.
    Nicholas T, Van Dam MK, Friedman AK, et al. Targeting KCNQ channels with retigabine (also called ezogabine) has antidepressant efficacy in depressed patients. Annual Meeting of Society of Biological Psychiatry; 2016; Atlanta, Georgia: SOBP Abstracts In Press.Google Scholar
  167. 167.
    Gu N, Vervaeke K, Hu H, Storm JF. Kv7/KCNQ/M and HCN/h, but not KCa2/SK channels, contribute to the somatic medium after-hyperpolarization and excitability control in CA1 hippocampal pyramidal cells. J Physiol. 2005;566(Pt 3):689-715.PubMedPubMedCentralCrossRefGoogle Scholar
  168. 168.
    Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology. 2012;62(1):35-41.PubMedCrossRefGoogle Scholar
  169. 169.
    Zhang K, Xu T, Yuan Z, et al. Essential roles of AMPA receptor GluA1 phosphorylation and presynaptic HCN channels in fast-acting antidepressant responses of ketamine. Sci Signal. 2016;9(458):ra123.Google Scholar
  170. 170.
    Chen X, Shu S, Bayliss DA. HCN1 channel subunits are a molecular substrate for hypnotic actions of ketamine. J Neurosci. 2009;29(3):600-9.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Bagot RC, Cates HM, Purushothaman I, et al. Ketamine and Imipramine Reverse Transcriptional Signatures of Susceptibility and Induce Resilience-Specific Gene Expression Profiles. Biol Psychiatry. 2017;81(4):285-95.PubMedCrossRefGoogle Scholar
  172. 172.
    Robison AJ, Vialou V, Sun HS, et al. Fluoxetine epigenetically alters the CaMKIIalpha promoter in nucleus accumbens to regulate DeltaFosB binding and antidepressant effects. Neuropsychopharmacology. 2014;39(5):1178-86.PubMedCrossRefGoogle Scholar
  173. 173.
    Wilkinson MB, Xiao G, Kumar A, et al. Imipramine treatment and resiliency exhibit similar chromatin regulation in the mouse nucleus accumbens in depression models. J Neurosci. 2009;29(24):7820-32.PubMedPubMedCentralCrossRefGoogle Scholar
  174. 174.
    Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50(4):260-5.PubMedCrossRefGoogle Scholar
  175. 175.
    Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM. Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry. 2008;63(7):642-9.PubMedCrossRefGoogle Scholar
  176. 176.
    Monteggia LM, Barrot M, Powell CM, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci U S A. 2004;101(29):10827-32.PubMedPubMedCentralCrossRefGoogle Scholar
  177. 177.
    Monteggia LM, Luikart B, Barrot M, et al. Brain-derived neurotrophic factor conditional knockouts show gender differences in depression-related behaviors. Biol Psychiatry. 2007;61(2):187-97.PubMedCrossRefGoogle Scholar
  178. 178.
    Taliaz D, Loya A, Gersner R, Haramati S, Chen A, Zangen A. Resilience to chronic stress is mediated by hippocampal brain-derived neurotrophic factor. J Neurosci. 2011;31(12):4475-83.PubMedCrossRefGoogle Scholar
  179. 179.
    Eisch AJ, Bolanos CA, de Wit J, et al. Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway: a role in depression. Biol Psychiatry. 2003;54(10):994-1005.PubMedCrossRefGoogle Scholar
  180. 180.
    Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001;7(5):541-7.PubMedCrossRefGoogle Scholar
  181. 181.
    Shah MM. HCN1 channels: a new therapeutic target for depressive disorders? Sci Signal. 2012;5(244):pe44.Google Scholar
  182. 182.
    Murrough JW, Abdallah CG, Mathew SJ. Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017.Google Scholar
  183. 183.
    Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015;172(10):950-66.PubMedCrossRefGoogle Scholar
  184. 184.
    Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov. 2011;10(12):903-14.PubMedGoogle Scholar
  185. 185.
    Baruscotti M, Bottelli G, Milanesi R, DiFrancesco JC, DiFrancesco D. HCN-related channelopathies. Pflugers Arch. 2010;460(2):405-15.PubMedCrossRefGoogle Scholar
  186. 186.
    Poolos NP. The Yin and Yang of the H-Channel and Its Role in Epilepsy. Epilepsy Curr. 2004;4(1):3-6.PubMedPubMedCentralCrossRefGoogle Scholar
  187. 187.
    Jiang YQ, Sun Q, Tu HY, Wan Y. Characteristics of HCN channels and their participation in neuropathic pain. Neurochemical research. 2008;33(10):1979-89.PubMedCrossRefGoogle Scholar
  188. 188.
    Noam Y, Bernard C, Baram TZ. Towards an integrated view of HCN channel role in epilepsy. Curr Opin Neurobiol. 2011;21(6):873-9.PubMedPubMedCentralCrossRefGoogle Scholar
  189. 189.
    Emery EC, Young GT, Berrocoso EM, Chen L, McNaughton PA. HCN2 ion channels play a central role in inflammatory and neuropathic pain. Science. 2011;333(6048):1462-6.PubMedCrossRefGoogle Scholar
  190. 190.
    Thorup L, Simonsen U, Grimm D, Hedegaard ER. Ivabradine: Current and Future Treatment of Heart Failure. Basic Clin Pharmacol Toxicol. 2017.Google Scholar
  191. 191.
    Guha K, Allen CJ, Hartley A, Sharma R. Ivabradine: A Current Overview. Curr Clin Pharmacol. 2016;11(4):241-9.PubMedCrossRefGoogle Scholar
  192. 192.
    Bois P, Guinamard R, Chemaly AE, Faivre JF, Bescond J. Molecular regulation and pharmacology of pacemaker channels. Curr Pharm Des. 2007;13(23):2338-49.PubMedCrossRefGoogle Scholar
  193. 193.
    Riccioni G, Vitulano N, D'Orazio N. Ivabradine: beyond heart rate control. Adv Ther. 2009;26(1):12-24.PubMedCrossRefGoogle Scholar
  194. 194.
    Pape HC. Specific bradycardic agents block the hyperpolarization-activated cation current in central neurons. Neuroscience. 1994;59(2):363-73.PubMedCrossRefGoogle Scholar
  195. 195.
    Harris NC, Constanti A. Mechanism of block by ZD 7288 of the hyperpolarization-activated inward rectifying current in guinea pig substantia nigra neurons in vitro. J Neurophysiol. 1995;74(6):2366-78.PubMedGoogle Scholar
  196. 196.
    Surges R, Freiman TM, Feuerstein TJ. Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells. Epilepsia. 2003;44(2):150-6.PubMedCrossRefGoogle Scholar
  197. 197.
    Food and Drug Administration FDA approves Corlanor to treat heart failure. Apr 15, 2015 [Available from:].
  198. 198.
    Bucchi A, Tognati A, Milanesi R, Baruscotti M, DiFrancesco D. Properties of ivabradine-induced block of HCN1 and HCN4 pacemaker channels. J Physiol. 2006;572(Pt 2):335-46.PubMedPubMedCentralCrossRefGoogle Scholar
  199. 199.
    Tibbs GR, Posson DJ, Goldstein PA. Voltage-Gated Ion Channels in the PNS: Novel Therapies for Neuropathic Pain? Trends Pharmacol Sci. 2016;37(7):522-42.PubMedCrossRefGoogle Scholar
  200. 200.
    Savelieva I, Camm AJ. I f inhibition with ivabradine : electrophysiological effects and safety. Drug safety. 2008;31(2):95-107.PubMedCrossRefGoogle Scholar
  201. 201.
    Jacob S, Nair AB. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R D. 2016;16(4):303-16.PubMedPubMedCentralCrossRefGoogle Scholar
  202. 202.
    Coderre TJ, Kumar N, Lefebvre CD, Yu JS. A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain. J Neurochem. 2007;100(5):1289-99.PubMedCrossRefGoogle Scholar
  203. 203.
    Atalay H, Solak Y, Biyik Z, Gaipov A, Guney F, Turk S. Cross-over, open-label trial of the effects of gabapentin versus pregabalin on painful peripheral neuropathy and health-related quality of life in haemodialysis patients. Clin Drug Investig. 2013;33(6):401-8.PubMedCrossRefGoogle Scholar
  204. 204.
    Maneuf YP, Luo ZD, Lee K. alpha2delta and the mechanism of action of gabapentin in the treatment of pain. Semin Cell Dev Biol. 2006;17(5):565-70.PubMedCrossRefGoogle Scholar
  205. 205.
    Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience. 2016;338:183-206.PubMedCrossRefGoogle Scholar
  206. 206.
    Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord. 2000;2(3 Pt 2):249-55.PubMedCrossRefGoogle Scholar
  207. 207.
    Carta MG, Hardoy MC, Hardoy MJ, Grunze H, Carpiniello B. The clinical use of gabapentin in bipolar spectrum disorders. J Affect Disord. 2003;75(1):83-91.PubMedCrossRefGoogle Scholar
  208. 208.
    Stanton SP, Keck PE, Jr., McElroy SL. Treatment of acute mania with gabapentin. Am J Psychiatry. 1997;154(2):287.PubMedGoogle Scholar
  209. 209.
    McElroy SL, Soutullo CA, Keck PE, Jr., Kmetz GF. A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann Clin Psychiatry. 1997;9(2):99-103.PubMedCrossRefGoogle Scholar
  210. 210.
    Ghaemi SN, Katzow JJ, Desai SP, Goodwin FK. Gabapentin treatment of mood disorders: a preliminary study. J Clin Psychiatry. 1998;59(8):426-9.PubMedCrossRefGoogle Scholar
  211. 211.
    Erfurth A, Kammerer C, Grunze H, Normann C, Walden J. An open label study of gabapentin in the treatment of acute mania. J Psychiatr Res. 1998;32(5):261-4.PubMedCrossRefGoogle Scholar
  212. 212.
    Young LT, Robb JC, Patelis-Siotis I, MacDonald C, Joffe RT. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry. 1997;42(9):851-3.PubMedCrossRefGoogle Scholar
  213. 213.
    Houghton KT, Forrest A, Awad A, et al. Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis. BMJ Open. 2017;7(3):e013433.PubMedPubMedCentralCrossRefGoogle Scholar
  214. 214.
    Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol. 2000;20(6):607-14.PubMedCrossRefGoogle Scholar
  215. 215.
    Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Harv Rev Psychiatry. 2009;17(4):231-41.PubMedCrossRefGoogle Scholar
  216. 216.
    Brannon N, Labbate L, Huber M. Gabapentin treatment for posttraumatic stress disorder. Can J Psychiatry. 2000;45(1):84.PubMedCrossRefGoogle Scholar
  217. 217.
    Hamner MB, Brodrick PS, Labbate LA. Gabapentin in PTSD: a retrospective, clinical series of adjunctive therapy. Ann Clin Psychiatry. 2001;13(3):141-6.PubMedCrossRefGoogle Scholar
  218. 218.
    Karam-Hage M, Brower KJ. Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients. Psychiatry Clin Neurosci. 2003;57(5):542-4.PubMedPubMedCentralCrossRefGoogle Scholar
  219. 219.
    Karam-Hage M, Brower KJ. Gabapentin treatment for insomnia associated with alcohol dependence. Am J Psychiatry. 2000;157(1):151.PubMedCrossRefGoogle Scholar
  220. 220.
    Pande AC, Pollack MH, Crockatt J, et al. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20(4):467-71.PubMedCrossRefGoogle Scholar
  221. 221.
    Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19(4):341-8.PubMedCrossRefGoogle Scholar
  222. 222.
    Pollack MH, Matthews J, Scott EL. Gabapentin as a potential treatment for anxiety disorders. Am J Psychiatry. 1998;155(7):992-3.PubMedCrossRefGoogle Scholar
  223. 223.
    Cora-Locatelli G, Greenberg BD, Martin J, Murphy DL. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder. J Clin Psychiatry. 1998;59(9):480-1.PubMedCrossRefGoogle Scholar
  224. 224.
    Cora-Locatelli G, Greenberg BD, Martin JD, Murphy DL. Rebound psychiatric and physical symptoms after gabapentin discontinuation. J Clin Psychiatry. 1998;59(3):131.PubMedCrossRefGoogle Scholar
  225. 225.
    Bowden CL, Calabrese JR, McElroy SL, et al. The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol Psychiatry. 1999;45(8):953-8.PubMedCrossRefGoogle Scholar
  226. 226.
    Calabrese JR, Bowden CL, McElroy SL, et al. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry. 1999;156(7):1019-23.PubMedGoogle Scholar
  227. 227.
    Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry. 1999;60(2):79-88.PubMedCrossRefGoogle Scholar
  228. 228.
    Pichler EM, Hattwich G, Grunze H, Muehlbacher M. Safety and tolerability of anticonvulsant medication in bipolar disorder. Expert Opin Drug Saf. 2015;14(11):1703-24.PubMedCrossRefGoogle Scholar
  229. 229.
    Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009;194(1):4-9.PubMedCrossRefGoogle Scholar
  230. 230.
    Walden J, Hesslinger B, van Calker D, Berger M. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry. 1996;29(5):193-5.PubMedCrossRefGoogle Scholar
  231. 231.
    Suppes T, Brown ES, McElroy SL, et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord. 1999;53(1):95-8.PubMedCrossRefGoogle Scholar
  232. 232.
    Fogelson DL, Sternbach H. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry. 1997;58(6):271-3.PubMedCrossRefGoogle Scholar
  233. 233.
    Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol. 1997;17(3):185-9.PubMedCrossRefGoogle Scholar
  234. 234.
    Kusumakar V, Yatham LN. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res. 1997;72(2):145-8.PubMedCrossRefGoogle Scholar
  235. 235.
    Labbate LA, Rubey RN. Lamotrigine for treatment-refractory bipolar disorder. Am J Psychiatry. 1997;154(9):1317.PubMedGoogle Scholar
  236. 236.
    Ketter TA, Manji HK, Post RM. Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders. J Clin Psychopharmacol. 2003;23(5):484-95.PubMedCrossRefGoogle Scholar
  237. 237.
    van der Loos ML, Mulder P, Hartong EG, et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord. 2011;13(1):111-7.PubMedCrossRefGoogle Scholar
  238. 238.
    van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009;70(2):223-31.PubMedCrossRefGoogle Scholar
  239. 239.
    Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord. 1998;51(3):333-43.PubMedCrossRefGoogle Scholar
  240. 240.
    Preston GA, Marchant BK, Reimherr FW, Strong RE, Hedges DW. Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord. 2004;79(1-3):297-303.PubMedCrossRefGoogle Scholar
  241. 241.
    Leiberich P, Nickel MK, Tritt K, Pedrosa Gil F. Lamotrigine treatment of aggression in female borderline patients, Part II: an 18-month follow-up. J Psychopharmacol. 2008;22(7):805-8.PubMedCrossRefGoogle Scholar
  242. 242.
    Tritt K, Nickel C, Lahmann C, et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol. 2005;19(3):287-91.PubMedCrossRefGoogle Scholar
  243. 243.
    Hahn CG, Gyulai L, Baldassano CF, Lenox RH. The current understanding of lamotrigine as a mood stabilizer. J Clin Psychiatry. 2004;65(6):791-804.PubMedCrossRefGoogle Scholar
  244. 244.
    Stahl SM. Anticonvulsants as mood stabilizers and adjuncts to antipsychotics: valproate, lamotrigine, carbamazepine, and oxcarbazepine and actions at voltage-gated sodium channels. J Clin Psychiatry. 2004;65(6):738-9.PubMedCrossRefGoogle Scholar
  245. 245.
    Kolivakis TT, Beauclair L, Margolese HC, Chouinard G. Long-term lamotrigine adjunctive to antipsychotic monotherapy in schizophrenia: further evidence. Can J Psychiatry. 2004;49(4):280.PubMedGoogle Scholar
  246. 246.
    Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial. Biol Psychiatry. 2003;54(11):1241-8.PubMedCrossRefGoogle Scholar
  247. 247.
    Premkumar TS, Pick J. Lamotrigine for schizophrenia. The Cochrane database of systematic reviews. 2006(4):CD005962.Google Scholar
  248. 248.
    Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry. 2013;74(7):675-84.PubMedCrossRefGoogle Scholar
  249. 249.
    Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2009;109(1-3):10-4.PubMedCrossRefGoogle Scholar
  250. 250.
    Mihara K, Nakamura A, Nemoto K, et al. Lamotrigine augmentation therapy in a case with treatment-resistant unipolar depression that showed insufficient response to electroconvulsive therapy. Psychiatry Clin Neurosci. 2016;70(2):126.PubMedCrossRefGoogle Scholar
  251. 251.
    Nakamura A, Mihara K, Nagai G, et al. Prediction of an Optimal Dose of Lamotrigine for Augmentation Therapy in Treatment-Resistant Depressive Disorder From Plasma Lamotrigine Concentration at Week 2. Ther Drug Monit. 2016;38(3):379-82.PubMedCrossRefGoogle Scholar
  252. 252.
    Ivkovic M, Damjanovic A, Jovanovic A, Cvetic T, Jasovic-Gasic M. Lamotrigine versus lithium augmentation of antidepressant therapy in treatment-resistant depression: efficacy and tolerability. Psychiatr Danub. 2009;21(2):187-93.PubMedGoogle Scholar
  253. 253.
    Barbee JG, Thompson TR, Jamhour NJ, et al. A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. J Clin Psychiatry. 2011;72(10):1405-12.PubMedCrossRefGoogle Scholar
  254. 254.
    Barbee JG, Jamhour NJ. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry. 2002;63(8):737-41.PubMedCrossRefGoogle Scholar
  255. 255.
    Hertzberg MA, Butterfield MI, Feldman ME, et al. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry. 1999;45(9):1226-9.PubMedCrossRefGoogle Scholar
  256. 256.
    Kumar TC, Khanna S. Lamotrigine augmentation of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Aust N Z J Psychiatry. 2000;34(3):527-8.PubMedCrossRefGoogle Scholar
  257. 257.
    Bruno A, Mico U, Pandolfo G, et al. Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. J Psychopharmacol. 2012;26(11):1456-62.PubMedCrossRefGoogle Scholar
  258. 258.
    Brown ES, Nejtek VA, Perantie DC, Orsulak PJ, Bobadilla L. Lamotrigine in patients with bipolar disorder and cocaine dependence. J Clin Psychiatry. 2003;64(2):197-201.PubMedCrossRefGoogle Scholar
  259. 259.
    Brown ES, Perantie DC, Dhanani N, Beard L, Orsulak P, Rush AJ. Lamotrigine for bipolar disorder and comorbid cocaine dependence: a replication and extension study. J Affect Disord. 2006;93(1-3):219-22.PubMedCrossRefGoogle Scholar
  260. 260.
    Brown ES, Sunderajan P, Hu LT, Sowell SM, Carmody TJ. A randomized, double-blind, placebo-controlled, trial of lamotrigine therapy in bipolar disorder, depressed or mixed phase and cocaine dependence. Neuropsychopharmacology. 2012;37(11):2347-54.PubMedPubMedCentralCrossRefGoogle Scholar
  261. 261.
    Margolin A, Avants SK, DePhilippis D, Kosten TR. A preliminary investigation of lamotrigine for cocaine abuse in HIV-seropositive patients. Am J Drug Alcohol Abuse. 1998;24(1):85-101.PubMedCrossRefGoogle Scholar
  262. 262.
    Krupitsky EM, Rudenko AA, Burakov AM, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31(4):604-11.PubMedGoogle Scholar
  263. 263.
    Kalyoncu A, Mirsal H, Pektas O, Unsalan N, Tan D, Beyazyurek M. Use of lamotrigine to augment clozapine in patients with resistant schizophrenia and comorbid alcohol dependence: a potent anti-craving effect? J Psychopharmacol. 2005;19(3):301-5.PubMedCrossRefGoogle Scholar
  264. 264.
    Rubio G, Lopez-Munoz F, Alamo C. Effects of lamotrigine in patients with bipolar disorder and alcohol dependence. Bipolar Disord. 2006;8(3):289-93.PubMedCrossRefGoogle Scholar
  265. 265.
    Brower KJ, Myra Kim H, Strobbe S, Karam-Hage MA, Consens F, Zucker RA. A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcohol Clin Exp Res. 2008;32(8):1429-38.PubMedPubMedCentralCrossRefGoogle Scholar
  266. 266.
    Brodie MS, Pesold C, Appel SB. Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol Clin Exp Res. 1999;23(11):1848-52.PubMedCrossRefGoogle Scholar
  267. 267.
    Hopf FW, Martin M, Chen BT, Bowers MS, Mohamedi MM, Bonci A. Withdrawal from intermittent ethanol exposure increases probability of burst firing in VTA neurons in vitro. J Neurophysiol. 2007;98(4):2297-310.PubMedCrossRefGoogle Scholar
  268. 268.
    Tu Y, Kroener S, Abernathy K et al. Ethanol inhibits persistent activity in prefrontal cortical neurons. J Neurosci. 2007;27(17):4765-75.PubMedPubMedCentralCrossRefGoogle Scholar
  269. 269.
    Yan H, Li Q, Fleming R, Madison RD, Wilson WA, Swartzwelder HS. Developmental sensitivity of hippocampal interneurons to ethanol: involvement of the hyperpolarization-activated current, Ih. J Neurophysiol. 2009;101(1):67-83.PubMedCrossRefGoogle Scholar
  270. 270.
    Berlin RK, Butler PM, Perloff MD. Gabapentin Therapy in Psychiatric Disorders: A Systematic Review. Prim Care Companion CNS Disord. 2015;17(5).Google Scholar
  271. 271.
    Williams AD, Jung S, Poolos NP. Protein kinase C bidirectionally modulates Ih and hyperpolarization-activated cyclic nucleotide-gated (HCN) channel surface expression in hippocampal pyramidal neurons. J Physiol. 2015;593(13):2779-92.PubMedPubMedCentralCrossRefGoogle Scholar
  272. 272.
    Chevaleyre V, Castillo PE. Assessing the role of Ih channels in synaptic transmission and mossy fiber LTP. Proc Natl Acad Sci U S A. 2002;99(14):9538-43.PubMedPubMedCentralCrossRefGoogle Scholar
  273. 273.
    Mellor J, Nicoll RA, Schmitz D. Mediation of hippocampal mossy fiber long-term potentiation by presynaptic Ih channels. Science. 2002;295(5552):143-7.PubMedCrossRefGoogle Scholar
  274. 274.
    Chen C. ZD7288 inhibits postsynaptic glutamate receptor-mediated responses at hippocampal perforant path-granule cell synapses. Eur J Neurosci. 2004;19(3):643-9.PubMedCrossRefGoogle Scholar
  275. 275.
    Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-84.PubMedCrossRefGoogle Scholar
  276. 276.
    Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48(2):155-65.PubMedCrossRefGoogle Scholar
  277. 277.
    Arnsten AF, Wang M. Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders. Annu Rev Pharmacol Toxicol. 2016;56:339-60.PubMedPubMedCentralCrossRefGoogle Scholar
  278. 278.
    Connor DF, Arnsten AF, Pearson GS, Greco GF. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. Expert Opin Pharmacother. 2014;15(11):1601-10.PubMedCrossRefGoogle Scholar
  279. 279.
    Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med. 2012;85(1):45-58.PubMedPubMedCentralGoogle Scholar
  280. 280.
    Han Y, Lyman K, Clutter M et al. Identification of Small-Molecule Inhibitors of Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels. J Biomol Screen. 2015;20(9):1124-31.PubMedPubMedCentralCrossRefGoogle Scholar
  281. 281.
    Santoro B, Hu L, Liu H, et al. TRIP8b regulates HCN1 channel trafficking and gating through two distinct C-terminal interaction sites. J Neurosci. 2011;31(11):4074-86.PubMedPubMedCentralCrossRefGoogle Scholar
  282. 282.
    Bankston JR, Camp SS, DiMaio F, Lewis AS, Chetkovich DM, Zagotta WN. Structure and stoichiometry of an accessory subunit TRIP8b interaction with hyperpolarization-activated cyclic nucleotide-gated channels. Proc Natl Acad Sci U S A. 2012;109(20):7899-904.PubMedPubMedCentralCrossRefGoogle Scholar
  283. 283.
    Han Y, Lyman KA, Clutter M et al. Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b. J Vis Exp. 2016(117).Google Scholar
  284. 284.
    Han Y, Noam Y, Lewis AS et al. Trafficking and gating of hyperpolarization-activated cyclic nucleotide-gated channels are regulated by interaction with tetratricopeptide repeat-containing Rab8b-interacting protein (TRIP8b) and cyclic AMP at distinct sites. J Biol Chem. 2011;286(23):20823-34.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2017

Authors and Affiliations

  1. 1.Department of Pharmacological Sciences and Institute for Systems BiomedicineIcahn School of Medicine at Mount SinaiNew YorkUSA
  2. 2.Fishberg Department of Neuroscience and Friedman Brain InstituteIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations